Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways

Timo Buhl, Mathias Sulk, Pawel Nowak, Jörg Buddenkotte, Ian McDonald, Jérôme Aubert, Isabelle Carlavan, Sophie Déret, Pascale Reiniche, Michel Rivier, Johannes J Voegel, Martin Steinhoff, Timo Buhl, Mathias Sulk, Pawel Nowak, Jörg Buddenkotte, Ian McDonald, Jérôme Aubert, Isabelle Carlavan, Sophie Déret, Pascale Reiniche, Michel Rivier, Johannes J Voegel, Martin Steinhoff

Abstract

Rosacea is a common chronic inflammatory skin disease of unknown etiology. Our knowledge about an involvement of the adaptive immune system is very limited. We performed detailed transcriptome analysis, quantitative real-time reverse-transcriptase-PCR, and quantitative immunohistochemistry on facial biopsies of rosacea patients, classified according to their clinical subtype. As controls, we used samples from patients with facial lupus erythematosus and healthy controls. Our study shows significant activation of the immune system in all subtypes of rosacea, characterizing erythematotelangiectatic rosacea (ETR) already as a disease with significant influx of proinflammatory cells. The T-cell response is dominated by Th1/Th17-polarized immune cells, as demonstrated by significant upregulation of IFN-γ or IL-17, for example. Chemokine expression patterns support a Th1/Th17 polarization profile of the T-cell response. Macrophages and mast cells are increased in all three subtypes of rosacea, whereas neutrophils reach a maximum in papulopustular rosacea. Our studies also provide evidence for the activation of plasma cells with significant antibody production already in ETR, followed by a crescendo pattern toward phymatous rosacea. In sum, Th1/Th17 polarized inflammation and macrophage infiltration are an underestimated hallmark in all subtypes of rosacea. Therapies directly targeting the Th1/Th17 pathway are promising candidates in the future treatment of this skin disease.

References

    1. Immunol Rev. 2013 Mar;252(1):116-32
    1. Dermatology. 2002;205(3):265-70
    1. J R Soc Med. 1997 Mar;90(3):144-50
    1. Dermatologica. 1984;169(1):1-5
    1. J Invest Dermatol. 2014 Apr;134(4):1143-5
    1. Br J Dermatol. 2012 Nov;167(5):1032-6
    1. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1336-43
    1. J Immunol. 2008 Jan 1;180(1):214-21
    1. Adv Immunol. 2011;111:179-206
    1. Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):97-106
    1. J Am Acad Dermatol. 2014 Jul;71(1):100-7
    1. Br J Dermatol. 2007 Sep;157(3):474-81
    1. N Engl J Med. 2005 Feb 24;352(8):793-803
    1. Int J Infect Dis. 2014 Dec;29:176-7
    1. Cancer Res. 2006 Apr 15;66(8):4450-60
    1. Infect Immun. 2011 Jul;79(7):2871-9
    1. J Leukoc Biol. 2010 Feb;87(2):223-35
    1. J Investig Dermatol Symp Proc. 2011 Dec;15(1):53-62
    1. J Biol Chem. 2001 Feb 2;276(5):2986-91
    1. J Invest Dermatol. 2011 Mar;131(3):688-97
    1. Immunol Rev. 2008 Dec;226:112-31
    1. J Investig Dermatol Symp Proc. 2011 Dec;15(1):40-7
    1. Exp Dermatol. 2011 Oct;20(10):789-94
    1. Blood. 2009 Mar 26;113(13):2955-64
    1. F1000Prime Rep. 2014 Jul 08;6:50
    1. Immunity. 2010 May 28;32(5):593-604
    1. Immunol Rev. 2000 Oct;177:195-203
    1. J Allergy Clin Immunol. 2003 Dec;112(6):1195-202
    1. J Invest Dermatol. 2014 Feb;134(2):366-73
    1. Nat Immunol. 2010 Nov;11(11):1014-22
    1. J Investig Dermatol Symp Proc. 2011 Dec;15(1):2-11
    1. Ophthalmology. 1990 Nov;97(11):1468-75
    1. J Invest Dermatol. 2012 Apr;132(4):1253-62
    1. Curr Opin Immunol. 2012 Apr;24(2):191-5
    1. J Am Acad Dermatol. 2000 Mar;42(3):468-72
    1. J Eur Acad Dermatol Venereol. 2001 Sep;15(5):441-4
    1. J Allergy Clin Immunol. 2013 Aug;132(2):361-70
    1. J Immunol. 2000 Feb 1;164(3):1488-97
    1. J Am Acad Dermatol. 2013 Dec;69(6):1025-32
    1. Br J Ophthalmol. 2007 Feb;91(2):226-9
    1. Mini Rev Med Chem. 2007 Nov;7(11):1089-96
    1. J Am Acad Dermatol. 2002 Apr;46(4):584-7
    1. Exp Dermatol. 2012 Dec;21(12):906-10
    1. Immunol Rev. 2012 Nov;250(1):102-19
    1. J Investig Dermatol Symp Proc. 2011 Dec;15(1):12-5
    1. J Am Acad Dermatol. 2013 Dec;69(6 Suppl 1):S15-26
    1. Immunol Rev. 2009 Mar;228(1):9-22
    1. Immunol Rev. 2007 Aug;218:45-64
    1. Arch Dermatol. 1969 Dec;100(6):683-91
    1. J Invest Dermatol. 2015 Jan;135(1):110-8
    1. J Med Microbiol. 2014 Feb;63(Pt 2):258-62
    1. PLoS One. 2014 Aug 25;9(8):e105238
    1. Nat Med. 2007 Aug;13(8):975-80
    1. Inflamm Res. 2006 Jun;55(6):221-7
    1. Biochem Biophys Res Commun. 2013 Apr 19;433(4):532-7
    1. Immunity. 2012 May 25;36(5):705-16
    1. BMC Genomics. 2013 Nov 23;14:825
    1. Cell Mol Immunol. 2010 Mar;7(2):100-3
    1. Acta Derm Venereol. 2014 Sep;94(5):512-6

Source: PubMed

3
Se inscrever